ClinicalTrials.gg
CompletedNCT00115765Updated Oct 17, 2018Results posted

PACCE: Panitumumab Advanced Colorectal Cancer Evaluation Study

A Phase 3 interventional study of Oxaliplatin Based Chemotherapy and Panitumumab in Colorectal Cancer, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,053
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 90 studies testing panitumumab in Colorectal Neoplasms — 7 open to participants now, 12 under way, 3 of them phase 3. Panitumumab · Colorectal Neoplasms.

Enrollment
4th of 88
1,053 · median 70
Started
2005
the only one that year
Phase 3
14 of 90
2 open now
Registered
9th of 90
by date
Lead sponsor
20 of 90
Amgen

Among the 90 studies testing panitumumab in Colorectal Neoplasms, this one is the 4th largest by enrollment of the 88 interventional ones that give a count, is the only one that started in 2005, is one of 14 in phase 3, and was the 9th registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

7 of the 90 studies testing panitumumab in Colorectal Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About panitumumab

Panitumumab: first FDA approval 2006 (VECTIBIX), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 90 studies testing panitumumab in Colorectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to assess whether treatment with the study drug, panitumumab given concomitantly with every 2 (Q2) week oxaliplatin-based chemotherapy and bevacizumab improves progression-free survival (PFS) compared to treatment Q2-week with oxaliplatin-based chemotherapy and bevacizumab alone. All subjects will receive Q2-week oxaliplatin- or irinotecan-based chemotherapy and bevacizumab. Control arm subjects will not receive concomitant panitumumab therapy.

03

Conditions studied

  • Colorectal Cancer

Keywords

  • Panitumumab Advanced Colorectal Cancer Evaluation Study (PACCE Study)
  • Colorectal, Colon, Rectal Cancer, Metastatic Colorectal
  • Cancer
  • EGFr, Clinical Trial
  • Panitumumab, ABX-EGF
  • Immunex, Abgenix, Amgen
  • Metastatic Colorectal Cancer
  • Oncology
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adenocarcinoma of the colon or rectum
  • colorectal cancer (mCRC)
  • per modified (RECIST) criteria
  • performance status of 0 or 1
  • Available paraffin-embedded tumor tissue (from primary tumor or metastasis) or unstained slides of paraffin-embedded tissue
  • If history of other primary cancer, subject will be eligible only if she or he has:

    • Curatively resected non-melanomatous skin cancer;
    • Curatively treated cervical carcinoma in situ;
    • Other primary solid tumor curatively treated with no known active disease present and no treatment administered for the last 5 years.
  • Adequate hematologic data as follows:

    • (ANC) greater than or equal to 1.5 x 10\^9 cells/L;
    • count greater than or equal to 100 x 10\^9/L;
    • greater than or equal to 9.0 g/dL. - Adequate renal function:
    • Serum creatinine less than or equal to 1.5 x (ULN);
    • Urinary protein dipstick of less than 2+ (if urinary dipstick 2+ or greater, then excretion of less than or equal to 1000 mg of protein per day as determined by 24-hour urine collection).
  • Adequate hepatic function:

    • Alkaline phosphatase less than or equal to 3 x ULN (if liver metastases, less than or equal to 5 x ULN);
    • (serum glutamic-oxaloacetic transaminase)(AST) less than or equal to 3 x ULN (if liver metastases, less than or equal to 5 x ULN);
    • Alanine aminotransferase (serum glutamic-pyruvic transaminase) (ALT) less than or equal to 3 x ULN (if liver metastases, less than or equal to 5 x ULN);
    • less than or equal to 2 x ULN. - Competent to comprehend, sign, and date an IRB-approved form
  • Before any study-specific procedure, the appropriate written informed consent must be obtained.

Exclusion criteria

Exclusion Criteria:

  • Prior chemotherapy or biologic (i.e., antibody or vaccine) treatment for mCRC disease - Last dose of or radiosensitizing chemotherapy less than 6 months before randomization - Radiotherapy within 14 days before randomization
  • Elective and/or planned major surgical procedure to be performed during the course of this trial (surgery that arises as needed or necessary during the course of the study, not agreed a priori, will not make the subject ineligible)
  • Major surgery within 28 days before randomization
  • Central nervous system
  • History of interstitial pneumonitis or pulmonary fibrosis or evidence of interstitial pneumonitis or pulmonary fibrosis on baseline chest X-ray or CT-scan
  • ascites
  • Preexisting bleeding diathesis or coagulopathy or the need for full-dose anticoagulation
  • Any of the following within 1 year before randomization:

    • Myocardial infarction;
    • Unstable angina;
    • Symptomatic congestive heart failure;
    • Serious uncontrolled cardiac arrhythmia;
    • Cerebrovascular accident or ;
    • Gastrointestinal ulcer or hemorrhage;
    • Hemoptysis;
    • Pulmonary embolism;
    • Deep vein thrombosis, or other significant thromboembolic event.
  • Regular use of non-steroidal anti-inflammatory agents
  • Female subject of , not abstinent, and not willing to use during the course of the study and for 6 months following the last dose of treatment
  • Female subject who is breast-feeding or who has positive serum pregnancy test 72 hours prior to randomization
  • Male subject, not abstinent, and not willing to use adequate contraception upon enrollment into this study and for 6 months following the last dose of first-line treatment
  • Subject known to be (HIV) positive
  • Subject allergic to panitumumab or any components of panitumumab formulation
  • History of any medical or psychiatric condition or laboratory abnormality that, in the opinion of the investigator, may increase the risks associated with study participation or study drug administration or may interfere with the conduct of the study or interpretation of study results
  • Subject unwilling or unable to comply with study requirements
  • Any kind of disorder that compromises the ability of the subject to give written and/or comply with the study procedures
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,053 participants (actual)

Study arms

  • Active comparator
    Oxaliplatin and bevacizumab without panitumumab

    Oxaliplatin-based chemotherapy and Bevacizumab Q2W alone.

    Drug: Oxaliplatin Based Chemotherapy · Drug: Bevacizumab

  • Experimental
    Irinotecan and bevacizumab plus panitumumab

    Irinotecan-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W

    Drug: Panitumumab · Drug: Irinotecan Based Chemotherapy · Drug: Bevacizumab

  • Active comparator
    Irinotecan and bevacizumab without panitumumab

    Irinotecan-based chemotherapy and Bevacizumab Q2W alone

    Drug: Irinotecan Based Chemotherapy · Drug: Bevacizumab

  • Experimental
    Oxaliplatin and bevacizumab plus panitumumab

    Oxaliplatin-based chemotherapy and Bevacizumab Q2W plus panitumumab 6mg/kg Q2W

    Drug: Oxaliplatin Based Chemotherapy · Drug: Panitumumab · Drug: Bevacizumab

Interventions

  • DrugOxaliplatin Based Chemotherapy

    Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.

    Also known as: FOLFOX 4, FOLFOX 5, Modified FOLFOX 6, FOLFOX 7, Oxaliplatin

  • PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.

    Also known as: pmab, Vectibix

  • DrugIrinotecan Based Chemotherapy

    Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.

    Also known as: FOLFIRI, Douillard

  • Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .

    Also known as: Avastin

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (Oxaliplatin)

    Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression

    Time frame: Overall study

  2. Objective Tumor Response Through Week 12 (Irinotecan)

    Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum

    Time frame: Overall Study

Secondary outcomes

  1. Overall Survival (Oxaliplatin)

    Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin

    Time frame: Overall study

  2. Objective Tumor Response Rate (Oxaliplatin)

    Best overall response of complete or partial response within oxaliplatin stratum

    Time frame: Overall study

  3. Time to Progression (Oxaliplatin)

    Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum

    Time frame: Overall Study

  4. Time to Treatment Failure (Oxaliplatin)

    Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum.

    Time frame: Overall study

  5. Overall Survival (Irinotecan)

    Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm.

    Time frame: Overall study

  6. Progression-free Survival (Irinotecan)

    Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression

    Time frame: Overall Study

  7. Objective Tumor Response Rate (Irinotecan)

    Best overall response of complete or partial response within irinotecan stratum

    Time frame: Overall Study

  8. Time to Progression (Irinotecan)

    Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum

    Time frame: Overall Study

  9. Time to Treatment Failure (Irinotecan)

    Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum

    Time frame: Overall Study

07

Results

Posted Sep 14, 2010

Participant flow

Participants were enrolled from 10 March 2005 through 19 October 2006.

Participant flow — Overall Study
MilestoneIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus Panitumumab
Started115413410115
Completed8031328984
Not completed3510012131
Withdrew: Withdrawal by subject22537615
Withdrew: Physician decision4151813
Withdrew: Lost to follow-up320181
Withdrew: Other61292

Outcome measures

PrimaryProgression-Free Survival (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression

Time frame:
Overall study
Reported as:
Median · Month
Progression-Free Survival (Oxaliplatin)
MonthOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Progression-Free Survival (Oxaliplatin)10.0 (8.9 to 11.0)11.4 (10.5 to 11.9)
Statistical analysis
  • Oxaliplatin and Bevacizumab Plus Panitumumab vs Oxaliplatin and Bevacizumab Without Panitumumab · Regression, Cox · p = 0.011 · Hazard ratio (hr): 1.27 · 95% CI 1.06 to 1.52Model covariates were ECOG status, prior chemotherapy, metastatic organs, disease site, oxaliplatin dose \< 85 mg/m2, and oxaliplatin dose \> 100 mg/m2
SecondaryOverall Survival (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin

Time frame:
Overall study
Reported as:
Median · Month
Overall Survival (Oxaliplatin)
MonthOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Overall Survival (Oxaliplatin)19.4 (18.4 to 20.8)24.5 (20.4 to 24.5)
Statistical analysis
  • Oxaliplatin and Bevacizumab Plus Panitumumab vs Oxaliplatin and Bevacizumab Without Panitumumab · Regression, Cox · p = 0.005 · Hazard ratio (hr): 1.43 · 95% CI 1.11 to 1.83Model covariates were ECOG status, prior chemotherapy, metastatic organs, disease site, oxaliplatin dose \< 85 mg/m2, and oxaliplatin dose \> 100 mg/m2
SecondaryObjective Tumor Response Rate (Oxaliplatin)

Best overall response of complete or partial response within oxaliplatin stratum

Time frame:
Overall study
Reported as:
Number · Participant
Objective Tumor Response Rate (Oxaliplatin)
ParticipantOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Objective Tumor Response Rate (Oxaliplatin)190196
SecondaryTime to Progression (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the oxaliplatin stratum

Time frame:
Overall Study
Reported as:
Median · Month
Time to Progression (Oxaliplatin)
MonthOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Time to Progression (Oxaliplatin)10.8 (9.5 to 11.3)11.4 (10.9 to 12.2)
SecondaryTime to Treatment Failure (Oxaliplatin)

Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the oxaliplatin stratum.

Time frame:
Overall study
Reported as:
Median · Month
Time to Treatment Failure (Oxaliplatin)
MonthOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Time to Treatment Failure (Oxaliplatin)5.7 (5.5 to 6.0)5.9 (5.7 to 6.2)
PrimaryObjective Tumor Response Through Week 12 (Irinotecan)

Objective tumor response (complete or partial) rate through week 12 based on central review in the Irinotecan stratum

Time frame:
Overall Study
Reported as:
Number · Participant
Objective Tumor Response Through Week 12 (Irinotecan)
ParticipantIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Objective Tumor Response Through Week 12 (Irinotecan)2927
Statistical analysis
  • Irinotecan and Bevacizumab Plus Panitumumab vs Irinotecan and Bevacizumab Without Panitumumab · Regression, Logistic · p = 0.738 · Odds ratio (or): 1.11 · 95% CI 0.60 to 2.05Model covariates were ECOG status, prior adjuvant chemotherapy, number of metastatic organs, and primary disease site
SecondaryOverall Survival (Irinotecan)

Incidence of mortality from any cause in groups treated with Irinotecan. Incidence is provided in lieu of the median time to death since the median or its measure of dispersion was not estimable for at least one treatment arm.

Time frame:
Overall study
Reported as:
Number · Participant
Overall Survival (Irinotecan)
ParticipantIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Overall Survival (Irinotecan)2618
Statistical analysis
  • Irinotecan and Bevacizumab Plus Panitumumab vs Irinotecan and Bevacizumab Without Panitumumab · Regression, Cox · p = 0.257 · Hazard ratio (hr): 1.42 · 95% CI 0.77 to 2.62Model covariates were ECOG status, prior adjuvant chemotherapy, number of metastatic organs, and primary disease site
SecondaryProgression-free Survival (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression

Time frame:
Overall Study
Reported as:
Median · Month
Progression-free Survival (Irinotecan)
MonthIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Progression-free Survival (Irinotecan)10.1 (8.2 to 13.7)11.7 (9.0 to 13.2)
Post-hocProgression-free Survival (Wild-type KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)

Time frame:
Overall Study
Reported as:
Median · Month
Progression-free Survival (Wild-type KRAS)
MonthOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Progression-free Survival (Wild-type KRAS)9.8 (8.4 to 11.3)11.5 (10.6 to 12.3)
Statistical analysis
  • Oxaliplatin and Bevacizumab Plus Panitumumab vs Oxaliplatin and Bevacizumab Without Panitumumab · Hazard ratio (hr): 1.36 · 95% CI 1.04 to 1.77
Post-hocProgression-free Survival (Mutant KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause or first observed disease progression in groups treated with oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)

Time frame:
Overall Study
Reported as:
Median · Month
Progression-free Survival (Mutant KRAS)
MonthOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Progression-free Survival (Mutant KRAS)10.4 (9.1 to 11.3)11.0 (9.9 to 12.8)
Statistical analysis
  • Oxaliplatin and Bevacizumab Plus Panitumumab vs Oxaliplatin and Bevacizumab Without Panitumumab · Hazard ratio (hr): 1.25 · 95% CI 0.91 to 1.71
Post-hocOverall Survival (Wild-type KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median

Time frame:
Overall Study
Reported as:
Number · Participant
Overall Survival (Wild-type KRAS)
ParticipantOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Overall Survival (Wild-type KRAS)7146
Statistical analysis
  • Oxaliplatin and Bevacizumab Plus Panitumumab vs Oxaliplatin and Bevacizumab Without Panitumumab · Hazard ratio (hr): 1.89 · 95% CI 1.30 to 2.75
Post-hocOverall Survival (Mutant KRAS)

Kaplan-Meier estimate of the median time from randomization to death from any cause in groups treated with Oxaliplatin and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS). Since the measure of dispersion could not be estimated for at least one treatment arm, participant incidence is provided in lieu of the median.

Time frame:
Overall Study
Reported as:
Number · Participant
Overall Survival (Mutant KRAS)
ParticipantOxaliplatin and Bevacizumab Plus PanitumumabOxaliplatin and Bevacizumab Without Panitumumab
Overall Survival (Mutant KRAS)4745
Statistical analysis
  • Oxaliplatin and Bevacizumab Plus Panitumumab vs Oxaliplatin and Bevacizumab Without Panitumumab · Hazard ratio (hr): 1.02 · 95% CI 0.67 to 1.54
Post-hocObjective Tumor Response Rate (Wild-type KRAS)

Best overall response of complete or partial response in participants treated with irinotecan and having a wild-type Kirsten Rat Sarcoma Virus Oncogene (KRAS)

Time frame:
Overall Study
Reported as:
Number · Participant
Objective Tumor Response Rate (Wild-type KRAS)
ParticipantIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Objective Tumor Response Rate (Wild-type KRAS)3128
Statistical analysis
  • Irinotecan and Bevacizumab Plus Panitumumab vs Irinotecan and Bevacizumab Without Panitumumab · Odds ratio (or): 1.28 · 95% CI 0.61 to 2.66
Post-hocObjective Tumor Response Rate (Mutant KRAS)

Best overall response of complete or partial response in participants treated with irinotecan and having a mutant Kirsten Rat Sarcoma Virus Oncogene (KRAS)

Time frame:
Overall Study
Reported as:
Number · Participant
Objective Tumor Response Rate (Mutant KRAS)
ParticipantIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Objective Tumor Response Rate (Mutant KRAS)1415
Statistical analysis
  • Irinotecan and Bevacizumab Plus Panitumumab vs Irinotecan and Bevacizumab Without Panitumumab · Odds ratio (or): 0.68 · 95% CI 0.28 to 1.67
SecondaryObjective Tumor Response Rate (Irinotecan)

Best overall response of complete or partial response within irinotecan stratum

Time frame:
Overall Study
Reported as:
Number · Participant
Objective Tumor Response Rate (Irinotecan)
ParticipantIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Objective Tumor Response Rate (Irinotecan)4946
SecondaryTime to Progression (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to disease progression or death due to disease progression within the irinotecan stratum

Time frame:
Overall Study
Reported as:
Median · Month
Time to Progression (Irinotecan)
MonthIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Time to Progression (Irinotecan)11.1 (8.3 to 14.1)11.9 (9.0 to 13.2)
SecondaryTime to Treatment Failure (Irinotecan)

Kaplan-Meier estimate of the median time from randomization to the date the decision was made to discontinue treatment for a reason other than a complete response to treatment within the irinotecan stratum

Time frame:
Overall Study
Reported as:
Median · Month
Time to Treatment Failure (Irinotecan)
MonthIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without Panitumumab
Time to Treatment Failure (Irinotecan)6.6 (5.9 to 8.0)6.0 (4.8 to 6.9)

Adverse events

Collected over First dose through maximum of safety FU or 30 days after last dose. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Panit. Plus Bevacizumab With Chemotherapy—306/518 (59.1%)516/518 (99.6%)
Bevacizumab With Chemotherapy—188/510 (36.9%)505/510 (99%)
Most frequent serious events
Showing 10 of 341
Most frequent serious events
EventPanit. Plus Bevacizumab With ChemotherapyBevacizumab With Chemotherapy
DEHYDRATIONMetabolism and nutrition disorders72/51821/510
DIARRHOEAGastrointestinal disorders63/51815/510
PULMONARY EMBOLISMRespiratory, thoracic and mediastinal disorders35/51817/510
VOMITINGGastrointestinal disorders27/51810/510
NAUSEAGastrointestinal disorders24/5187/510
ABDOMINAL PAINGastrointestinal disorders23/51817/510
FEBRILE NEUTROPENIABlood and lymphatic system disorders20/5189/510
DEEP VEIN THROMBOSISVascular disorders17/51812/510
PYREXIAGeneral disorders16/5189/510
SEPSISInfections and infestations16/5188/510
Most frequent other events
Showing 10 of 86
Most frequent other events
EventPanit. Plus Bevacizumab With ChemotherapyBevacizumab With Chemotherapy
DIARRHOEAGastrointestinal disorders385/518350/510
FATIGUEGeneral disorders354/518371/510
NAUSEAGastrointestinal disorders359/518368/510
RASHSkin and subcutaneous tissue disorders331/51871/510
CONSTIPATIONGastrointestinal disorders217/518187/510
VOMITINGGastrointestinal disorders215/518199/510
ANOREXIAMetabolism and nutrition disorders211/518155/510
NEUTROPENIABlood and lymphatic system disorders179/518207/510
DERMATITIS ACNEIFORMSkin and subcutaneous tissue disorders179/5187/510
ANAEMIABlood and lymphatic system disorders177/518147/510

Baseline characteristics

Age, Continuous
Age, Continuous(Year)Oxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabTotal
Mean61.0 ± 11.959.4 ± 11.757.8 ± 12.060.8 ± 11.760.4 ± 11.8
Sex: Female, Male
Sex: Female, Male(Participants)Oxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabTotal
Female1725944180455
Male2385671233598
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participant)Oxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabTotal
White or Caucasian3308685343844
Black or African American41181635110
Hispanic or Latino256142570
Asian10201022
Japanese20002
American Indian or Alaska Native12003
Native Hawaiian or Other Pacific Islander10001
Other01001
ECOG Score
ECOG Score(Participant)Oxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabTotal
02396874253634
11714741160419
Number of Metastatic Organs
Number of Metastatic Organs(Participant)Oxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabTotal
None00011
11994653204502
>12116962208550
Primary Site of Disease
Primary Site of Disease(Participant)Oxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabTotal
Colon3269295322835
Rectal84232091218
Prior adjuvant chemotherapy
Prior adjuvant chemotherapy(Participant)Oxaliplatin and Bevacizumab Without PanitumumabIrinotecan and Bevacizumab Plus PanitumumabIrinotecan and Bevacizumab Without PanitumumabOxaliplatin and Bevacizumab Plus PanitumumabTotal
Yes77383680231
No3337779333822
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol. 2009 Feb 10;27(5):672-80. doi: 10.1200/JCO.2008.19.8135. Epub 2008 Dec 29. PubMed 19114685 ↗
  • Abdel-Rahman O. Effect of Body Mass Index on 5-FU-Based Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer; A Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 2019 Dec;18(4):e385-e393. doi: 10.1016/j.clcc.2019.07.005. Epub 2019 Jul 15. PubMed 31378656 ↗
  • Abdel-Rahman O. Impact of Sex on Chemotherapy Toxicity and Efficacy Among Patients With Metastatic Colorectal Cancer: Pooled Analysis of 5 Randomized Trials. Clin Colorectal Cancer. 2019 Jun;18(2):110-115.e2. doi: 10.1016/j.clcc.2018.12.006. Epub 2018 Dec 28. PubMed 30679026 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2005 to primary completion in May 2007, 23 months.

Results were first posted in Sep 2010, 3 years 3 months after primary completion.

Of 69 industry-sponsored phase 3 interventional studies under Colorectal Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 54. This study's 23 months is below that.

Counting every sponsor, half of 175 studies reached it within 50 months; a quarter within 35 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2005
First posted
Jun 27, 2005
StartActual
Jun 1, 2005
Primary completionActual
May 31, 2007
CompletionActual
May 1, 2009
Results first posted
Sep 14, 2010
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00115765
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 27, 2005
Start date
Jun 1, 2005
Primary completion
May 31, 2007
Completion
May 1, 2009
Results posted
Sep 14, 2010
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Panitumumab

Start the discussion